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ABSTRACT  
“ comparative  study  of mifepristone  and  vaginal misoprostol  combination  over 
vaginal  misoprostol  alone  in first  trimester abortion ” 
 
To assess the efficacy of mifepristone vaginal misoprostol  in first trimester abortion. 
To compare this combination  with  vaginal misoprostol  alone for first trimester MTP. 
To compare the various parameters involved in MTP in both the methods and asses  the most suitable       
 methods for first trimester MTP. 
I. 50 mifepristone + misoprostol group 
II. 50misoprostol group 
Mifepristone + misoprostol  
Day 1 – 200 mg mifepristone was given orally  
Day 3 – 400 microgram of misoprostol kept vaginally and abserve 4 hours in op department. 
Misoprostol group  
400 microgram of misoprostol in posterior fornix repeated 4 to 6 hours apart after admission of patient in 
ward. Maximum of 3 doses  
Following were the observations of this study. 
1. Most of the patients were in the age group 21-30 and parous 
2. 4% of patients were unmarried who responded well for medical methods. 
3. Almost all patients had various symtoms in both groups. 
4. Expulsion was complete in the Mifepristone+Misoprostol group with only 2 
woman needing check curettage for confirmation of complete abortion. However 
in one women, there was no response and their pregnancy was terminated by 
MVA. On the other hand 48% of women in the Misoprostol alone group had to 
have curettage for completing the abortion process, and 10% of patients there was 
no response. 
5. Induction-abortion time is less in patients with Mifepristone +Misoprostol than 
Misoprostol alone (4-5 hours vs 20-22 hrs. respectively). 
6. None of the patients needed blood transfusion or volume expanders. 
7. None of the patients had delayed bleeding after 45 days. On an average Bleeding 
stopped within 2 to5 days of expelling products. 
8. Misoprostol is less expensive and efficacious. However induction abortion interval 
is prolonged than Mifepristone +Misoprostol combination. 
9. Though Mifepristone is more expensive, the high complete abortion rate and 
expulsion withing 4-5 hrs of Misoprostol administration makes it a preferred 
method where cost is not a restraining factor. 
1. Mifepristone-Misoprostol combination is an effective out-patient procedure for 
early MTP and is ideal for home management. 
2. Complete abortion rate is high with this combination. 
3. Similarly the induction abortion interval with this method is also less. 
4. Other associated complications are less. 
The only confounding factor is the cost involved which is about 20 times that of 
Misoprostol alone. 
 This makes the routine use of Mifepristone-Misoprostol combination for first 
trimester abortion an effective option where cost is not a consideration or in situations 
where and early abortion is required. 
Keywords 
First trimester abortion  
Mifepristone  
Vaginal misoprostone 
Comparison  
Complete abortion    
Post – aortal complications  
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INTRODUCTION 
 MTP act can have an impact on reduction of maternal mortality and 
morbidity through safe abortion. 
 Where abortion is legal, it is generally reasonably safe, where it is 
illegal, complications are common, and about 78,000 women die every year 
from these complications. 
 Regardless of personal feelings about the ethics of interrupting  
pregnancy professionals have duty to know the medical facts about abortion 
and share them with their patients. 
 Worldwide, about 46 million women have abortions each year, and 
about half of these procedures are illegal and considered “unsafe” by the World 
Health Organization. 
 Unsafe abortion is a “procedure for terminating an unwanted pregnancy 
either by person lacking the necessary skills or in an environment lacking the 
minimal medical standards or both.”                                                                                              
GLOBAL ABORTION SCENARIO 
 Globally out of 210 million pregnancies, that occur each year, about 46 
million (22%) end in induced abortion of which 20 million is estimated to be 
unsafe. 
  2
 Majority of women are likely to have at least one abortion by the time 
they are 45 years. It is unfortunate and disheartening to note that in spite of 
liberalized abortion rules there is still one unsafe abortion for every 7 live birth. 
INDIAN ABORTION SCENARIO 
 3.1 lakh legal abortions are being performed every year with an abortion 
rate of 2.3 / 1000 pregnancy. 
 4.6 million Illegal abortions are being performed every year with an 
illegal abortion rate of 130-200 / 1000 pregnancy. 
MATERNAL MORTALITY 
 Due to legal abortion     –   0.7/100,000 
 Due to criminal abortion –  500 / 100,000.  
 In developing countries, risk of death following complication of unsafe 
abortion procedure is much higher than when the abortion was performed 
professionally under safe condition. Complication of unsafe abortions may lead 
to sequel such as infertility, chronic PID, TO mass etc. Hence safe and simple 
abortion procedures and techniques for early-induced abortion are the need of 
the hour. When performed by trained health care providers with proper 
equipment, correct techniques and scrutinizing standard, abortion is one of the 
safest medical procedures. 
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Safe abortion services as provided by law should be: 
 Easily available  
 By well trained health care providers  
 Regulation of health systems. 
 Infrastructure including equipments and supplies 
METHODS AVILABLE FOR FIRST AND SECOND TRIMESTER MTP 
FIRST TRIMESTER  
1. Menstrual regulation 
2. Manual / Electrical vacuum aspiration 
3. Dilatation and curettage. 
4. Laminaria tent and prostaglandins for cervical dilatation. 
5. Medical methods. 
SECOND TRIMESTER 
1. Extra amniotic instillation of ethacridine lactate 1% or 2% 
2. Intra amniotic instillation of various agents. 
3. Prostaglandins in various combination. 
4. Mechanical devices like laminaria tents, catheters.  
5. Aspirotomy. 
6. Hysterotomy. 
 Many surgical methods of first trimester MTP have been associated with 
complications like 
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 Excessive Bleeding 
 Uterine perforation. 
 Syncopal attacks. 
 Shock. 
 Infection. 
 Incompetence of os. 
 Cervical Stenosis. 
 Ashermann syndrome. 
 Chronic Pelvic Inflammatory disease. 
 Infertility.  
 Abortion in the first trimester is safe compared to that in the second 
trimester and medical methods are still safer than surgical techniques. 
 Medical methods are safe, efficient, simple and results usually in 
complete abortion of the various medical methods. Mifepristone and 
Misoprostol have largely replaced other procedures. Both Mifepristone and 
Misoprostol have been used singly in various doses and also in combination 
dosage schedule. There are many studies for both and each study claims its 
schedule to be superior and safer than others. 
This study is taken to compare the efficacy, complications and complete 
abortion rate of Mifepristone and Misoprostol combination and Misoprostol 
alone in first trimester MTP. 
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REVIEW OF LITERATURE 
 In India the MTP act was passed by parliament in 1971 and came into 
force on 1st April 1972. 
HISTORY 
 To reduce high maternal mortality associated with abortion, Govt. of 
India set up. 
¾ Shantilal Shah committee in 1964, which recommended 
liberalization of abortion law to decrease MMR. 
¾ Bill presented in Rajya Sabha, and Lok Sabha, in 1969. 
¾ Act passed by parliament in August 1971, Implemented in April 
1972 all over India. 
¾ Revised in 1975. 
¾ The act was amended in December 2002, and rules in June 2003. 
I CONDITIONS UNDER WHICH PREGNANCY CAN BE 
 TERMINATED 
(a) Medical Grounds  
 Continuing of pregnancy might endanger the life of pregnant women. 
 Can cause grave injury to physical and mental health like, cardiac, renal 
diseases, diabetes, psychiatric illness. 
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(b) Eugenic Grounds 
 Risk of child being born with serious physical and mental handicap, 
hereditary disorder, viral infection. 
(c) Humanitarian Grounds  
 Pregnancy due to rape or incest. 
(d) Social Grounds  
 Risk or injury to mental health of pregnant women. 
 Failure of any contraceptive method. 
PROTECTIVE UMBRELLA OF MTP ACT 
 Even today voluntarily “Causing miscarriage to a woman with child 
other than in good faith for the purpose of saving her life” is a crime under 
section 312 of IPC. Punishable with fine and/or imprisonment. 
II WHO CAN PERFORM MTP 
 Any Registered medical practitioner with the following qualifications 
and/ or experience, 
         ~Who has completed six months of ‘House Surgeoncy’ in Obstetrics and 
Gynaecology. 
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        ~ Who had experience at any hospital for a period not less than one year in 
the practice of Obstetrics and Gynaecology.  
        ~ Who has assisted a RMP in the performance of 25 cases of MTP out of 
which at least five have been performed independently, in a hospital 
established or maintained, or  
A training institute approved by the Government (enabling to do only up to 12 
wks of gestation). 
              ~Who holds a PG Diploma or Degree in Obstetrics and Gynaecology. 
III. WHERE CAN BE PERFORMED? 
(a) A hospital established or maintained by government, or 
(b) At places approved by ‘District Level Committee’ 
 These rules in existence since 1972 were amended in 2002 and 2003 to 
incorporate some newer requirements to MTP and also to plug the lacunae and 
loopholes in the existing act. 
HIGHLIGHTS OF NEW RULES ARE 
Composition and tenure of District level committee( 3-5 members) 
1. One member of District level committee shall be gynaecologist / 
surgeon/ anesthetist. 
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2. Other members from the local medical profession, non-governmental 
 organization and panchayat institution. 
3.        One member of the committee should be a woman. 
 The tenure of the committee would be for two calendar years and the 
tenure of the   NGO member shall not be for more than two terms. 
APPROVED PLACE                    
 up to  7 weeks – conservative with RU-486 by RMP at his clinic 
with access to  approved place. 
 up to 12 weeks – place approved with  the following facilities, 
            - Gynaecology examination table/ labour table. 
            -  Resuscitation and sterilization equipments. 
            -  Drugs and Parenteral fluids. 
            - Backup facilities for treatment of shock and facilities for 
  transportation. 
 Up to 20 weeks -approved place with the following facilities: 
            - An operation table and instruments for performing  
  abdominal or Gynaecological surgery,      
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            - Anaesthetic equipments, Resuscitation and sterilization 
  equipments; and 
- Drugs and parenteral fluids for emergency use, as notified 
 by government of India from time to time.    
FOR MEDICAL ABORTION 
 The clinic where an approved registered medical practitioner prescribes 
medical drugs does not need a approval. 
EXPERIENCES 
Up to 20 weeks 
 A practitioner should hold PG degree / diploma in obstetrics and 
gynaecology. 
 A practitioner who has completed 6 months of house surgency in 
obstetrics and gynaecology. 
 A practitioner  who has at least one year experience in practice of 
obstertrics and gynaecology. 
Up to 12 Weeks 
 Practitioner who has assisted registered medical practitioner in the 
performance of 25 cases of MTP, of which at least five has been performed 
independently in hospital established or maintained by the Govt. 
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RCOG GUIDELINES FOR MEDICAL ABORTION 
INFORMATION FOR WOMEN 
 Verbal advice and printed information has to be given to women 
 Information to women about procedure  
 Confidentiality 
 Informed consent  
GESTATION AGE < 7 WEEKS 
• Medical abortion using Mifepristone –Misoprostol  is  an appropriate   
method 
• Conventional suction termination should be avoided at gestation of < 7 
weeks. 
• Surgical abortion using rigorous protocol may also be an appropriate 
method for early termination of pregnancy.  
RIGOROUS PROTOCOL CONSISTS OF 
 Pregnancy testing  
 USG before procedure 
Inspection of products of conception aspirated using magnification  
Follow up with β HCG if gestational sac is not clearly seen. 
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RECOMMENDED REGIMENS FOR EARLY MEDICAL ABORTION  
a. 200 mg Mifepristone orally followed by prostaglandin is  
  adequate. 
b. Misoprostol, a PG analogue given vaginally is a cost effective 
alternative for all abortion procedures.  
 200 mg of Mifepristone is as effective as 600 mg and evidence shows 
that Mifepristone given vaginally is a cost effective alternate to Gemeprost. 
(Crenin and Edwards)1 
 Combining Mifepristone with Misoprostol produce higher rate of 
complete  abortion, than when Misoprostol alone is used for this indication. 
Complete abortion rate for Mifepristone – Misoprostol at < 49 days  was 96% 
and it decreases to 85% at > 57 days. The incomplete abortion rate increases 
from 2.9 to 10% and method failure rise from 1.1 to 7.2 % with this regimen as 
gestational age increases. 
 The addition of more doses of Misoprostol to the Mifepristone - 
Misoprostol regimen did increase the success rate and reduce both incomplete 
abortion rate and method failure rate. However incomplete abortion is less with 
vaginal misoprostol. 
                                                                        - Meta analysis. Kahn et al.2000.2 
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COMPLICATION AND SEQUELAE (ROYAL COLLEGE OF 
OBSTETRICS AND GYNAECOLOGY) 
Hemorrhage                   Around 1.5 / 1000 abortions 
                                         Rate is less in early abortion 
                                        < 13 weeks 1.2 /1000 abortions 
                                        >20 weeks 8.5 / 1000 abortions 
Failed or continuation of pregnancy 
Medical  abortion  6.0/1000 
Post abortion sequel 
PID  upto  10% 
Rate is decreased when prophylactic antibiotics are used. 
Future reproductive performance 
 No proven association between induced abortion and subsequent 
preterm delivery or infertility. 
Psychological Sequel 
 Only a small percentage of women experience a feeling of guilt. 
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METHODS OF FIRST TRIMESTER ABORTION 
Medical methods 
• Prostaglandins  
• Methotrexate 
• Mifepristone (RU 486) 
• Mifepristone with PG analogues.  [Ashok Et al 1998 and other 
studies]3,9 
PROSTAGLANDINS 
 Blanchard K et al feels that Misoprostol when used alone hold promise 
for early termination of pregnancy. ( Blanchard K et al 2000).10 
           Various studies using 800 microgram of Misoprostol administered 24 to 
48 hrs apart shows success rates between 85% and 92% percentage-- Ngai SW 
et al., 2000.11 
 Tang and Ho tried 400 microgram of Misoprostol up to maximum of 5 
doses sublingually for second trimester abortion with success rate of 100%.12 
 The prostaglandins other than Misoprostol like Gemeprost – was tried in 
various regimens. (Kuldipsingh et al BJOG, Feb – 2003).13 
 Misoprostol  is  effective, less expensive than Gemeprost and it does not 
need refrigeration – ( RCOG 2004).14 
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METHOTREXATE 
 Methotrexate  (both oral and intra muscular) combined with Misoprostol 
have been under investigation since 1993 with complete abortion rates similar 
to Mifepristone regimens for pregnancies up to 49 days gestation.(CreninMd, 
et. al 2000).15 
 50 mg/m body surface area of Methotrexate followed by 800 microgram 
of Misoprostol from day 3 to day 7, have shown to result in complete abortions 
in 83 to 96% of cases.(Crenin Md, 2000 and other studies)15-19 
 It was observed that abortion using Methotrexate and Misoprostol takes 
longer and may take up to 5 weeks in 20 to 30% of women. 
 Use of Methotrexate for first trimester abortion is only of academic 
interest since WHO toxicity panel recommended against Methotrexate use due 
to its teratogenicity. 
MIFEPRISTONE 
 Mifepristone an antiprogestin  currently being used extensively for first 
trimester MTP. It acts by binding with progesterone receptor and inhibits the 
action of progestin, hence interface with the continuation of pregnancy. 
 After confirming the eligibility to undergo medical abortion, 600 mg of 
Mifepristone is administered orally or day 1. 
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 On day 3, the patent is assessed for the possibility of pregnancy 
expulsion, which occurs in 2 to 5% of patients with Mifepristone alone. 
MIFEPRISTONE WITH PG ANALOGUES 
 This is the most widely accepted method of early medical abortion. 
 Original protocol is 600 mg of Mifepristone orally on day 1 followed by 
prostaglandin analogues on day 3. This has been associated with a success rate 
of 95% (Trussell and Ellertson 1989).7 
 In order to reduce the cost of 600 mg of Mifepristone lower dose was 
tried. 
 Later it was thought that 200 mg of Mifepristone is as efficacious as 600 
mg of Mifepristone –(MC Kinley et. al 1993).20 
 Then Mifepristone in the doses of 200, 400 & 600 were tried followed 
by a vaginal Gemeprost 48 hrs later. The success rate of above dosage 
regimens was found to be 93.8%, 94.1% and 94.3% respectively. The overall 
continuation of pregnancy rate was 0.4% in all the regimens.(WHO task force 
on post-ovulatory method of fertility, BMI, 1993)21. 
 Two large trials with 2000 clients also confirmed the efficacy of 200 
milligram of oral Mifepristone with Misoprostol vaginally (Ashok PW3, Schaff 
EA22, CContraception1999). 
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 There was a randomized trial conducted in order to reduce the doses of 
Mifepristone to 50 mg orally followed 48 hrs later by Gemeprost for early 
medical abortion. However the relative risk of failure with lower dose was 
calculated to be 1.6 times the higher dose. (WHO task force on postovulatory 
method for fertility regulation, BJOG,2001).23 
 A large randomized study as to the most effective route of 
administration of Misoprostol following Mifepristone was conducted in which 
800 microgram of Misoprostol was administered vaginally or orally. The study 
found the vaginal route to be more efficacious with a complete abortion rate of 
93%. The same after oral route was 78%. The failure rates were also higher in 
the oral route (7%) compared to the vaginal administration of Misoprostol (1%) 
(EL Refaey, 1995).24  
 Many do not prefer Mifepristone and Sulprostone combination as there 
is a high rate of MI follows Sulprostone use.( Meta analysis, Kahn et at. 2000).2  
 The following combined regimen is recommended by RCOG for MTP 
with a pregnancy up to 9 completed weeks since LMO (2000).14 
 200 mg Mifepristone followed by 36 – 48 hrs by 1.0 mg of vaginal 
Gemeprost. 
OR 
800 mcg vaginal Misoprostol 
OR 
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400 mcg oral Misoprostol up to 7 weeks. 
All these were found to result in 98 % complete abortion 
(Trussell – Ellertson 1989)7 
Parity and success rates of early medical abortion  
Gestation Nulliparous  % Parous  % 
< 7 weeks  98.6 96.2 
7-8 weeks 98.3 93.1 
8-9 weeks 96.4 91.0 
> 9 weeks 73.3 83.0 
 
1. In Nulliparous women gestational age have no influence on the 
  outcome of pregnancy termination in early weeks. 
2. However after 9 weeks of pregnancy, there was a significantly 
  lower rate of complete abortion. 
3. In parous women the complete abortion rate was lower after 7 
  weeks. 
 (Bartely et at, contraception ,2000)25 
 Three regimens of Mifepristone + Misoprostol combination  for early 
medical  abortion was advocated by Helene et al. 
  18
REGIMEN I REGIMEN II REGIMEN III 
Ru 486 200 mg PO 
day 1 
+ 
800 mcg miso PO 
day 3 
+ 
400 mcg miso PO 
Bd 7 days 
Ru 486 200 mg PO. day 1 
+ 
800 mcg miso PV day 3 
+ 
400 mcg miso PO Bd 7 
days 
Ru 486 200 mg PO day 
1 
+ 
800 mcg miso PV day 
3 
 
Complete abortion 
rate 92% 
 
 
Complete abortion rate 
               94.7% 
 
Complete abortion rate 
               93.5% 
 
Helene et al BJOG, Sept 200326 
 However studies from ICMR has shown 200 mg of Mifepristione 
followed 36-48 hrs by 400 meg of oral or vaginal Misoprostol to be equally 
efficient with a Complete abortion rate of 95 % - 99% - ICMR 199427, Aubeny 
B. Baulieu 1991.28 
On Going Trials  
 A large multicentric trial by WHO on Mifepristone and Misoprostol as 
an abortificient in women with amenorrhoea up to 63 days is being conducted. 
The results may reveal more useful information on the efficacy of these drugs 
as a medical method of termination of early pregnancy.(WHO 1994)29 
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CONTRA INDICATION FOR MIFEPRISTIONE – MISOPROSTOL 
REGIMEN 
1. Severe anemia 
2. Adrenal failure 
3. Medical disease that preclude use of Misoprostol 
4. Suspected ectopic pregnancy 
5. Bleeding disorders (WHO, 2000)30 
SURGICAL METHODS OF FIRST TRIMESTER MTP 
1. Menstrual regulator (MR) 
2. Vacuum aspiration 
3. Suction evacuation / curettage 
IMMEDIATE COMPLICATIONS OF SURGICAL METHODS 
 1.        Excessive Bleeding  (a) Uterine atony  
     (b) Retained products of conception 
     (c) Uterine perforation 
     (d) Cervical laceration 
     (e) Post abortal syndrome 
2. Syncopal attacks 
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3. Shock 
4. Infection  
DELAYED COMPLICATION 
1. Incompetence of os  
2. Cervical Stenosis 
3. Ashermann Syndrome  
4. Chronic Pelvic Inflammatory Disease  
5. Infertility 
MIFEPRISTONE (RU -486) 
 Discovered by French biochemist Dr.Etienne-Emile Baulieu  consultant 
to Roussel Uclaf  company. Mifepristone is a 19 Nor-testosterone derivative 
[17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1-propynyl)-estra-
4,9-dien-3-one] which is an antiprogestin. Due to its high affinity for 
progesterone receptor it competitively binds them. 
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 The postulated mechanism of action is: 
  Stabilize receptor in non-DNA binding configuration 
       
    Prevents gene transcription  
       
   Antagonistic action on Endometrium & trophoblast 
       
    PG release  
                 
    Uterine contractions 
    
   Conceptus detach from uterine wall  
USES 
I ABORTIFACIENT 
¾ It acts on target cells of endometrium & decidua31 
¾ Affects the pituitary gonadotrophic cells producing remarkable 
decrease in LH level which results in leuteolysis and shedding of 
endometrium.31 
¾ Softens and ripens the cervix and produce increased release of 
myometrial prostaglandin resulting in expulsion of products of 
conception.32 
¾ It also increases the sensitivity of uterus to exogenous 
prostaglandins. 
¾ Anti glucocorticoid agent. 
¾ Weakly antiestrogenic34 
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 Rodger, Baird B.J.O.G, Baulieu EE. 1989 Medline, Henshaw RC, 
TempletonAA, Johnstudd, 1993. Baird 1993. 
II    CONTRACEPTIVE 
• Continuous administration of the drug in a dose of 20 mg from day1to30 
days inhibits ovulation and delays menstruation.35 
• Administration of 100 mg Mifepriston, 5 and 8 days after LH surge 
results in defective secretory endometrium.35  
• Each month, administration of the drug in late luteal phase induces 
menstruation whether or not pregnant.34 
• As an emergency contraceptive – 600 mg of Mifepristone within 72 hrs 
of unprotected coitus has 100% success rate. 
(Wolf JP.Contr.- Barid DT. Contraception 1993, Van Sankon and 
Haspel 1987 / IPPF Med Bull 1988).35-37 
III. CERVICAL DILATATION 
 To ripen the cervix prior to surgical method of MTP 
 Reduce the induction – abortion interval in medical method  
- Urquahat DL. Templeton AF Contraception 1990.38 
OTHER SYNERGISTIC USES  
 Endometriosis   -  Continuous use up to 3 months 
 
    - Kettle LM – Fertility – Sterility39/99/56 
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 Uterine leiomyoma  - 49% reduction of tumor size with 3-month 
       use. 
      - Howitz KB, Murphy Clinical Endocrin.40 
 Cushing’s syndrome  -   For unresectable humour 
  - Grun Berg Neuro Surgery 199141 
                                               - Neiman LK et. al, J. Clinical Endo 198542 
 For unruptured ectopic  -   Mifepristone instilled results in resolution 
         of  sac-trophoblast. 
 Glaucoma 
 Viral infections  
PHARMACOKINETICS 
 Following oral administration of Mifepristone it rapidly gets absorbed 
with peak plasma level of 1.89 in 90 minutes. 
 98% bound to plasma proteins – albumin an acid glycoprotein. 
 Following distribution phase, elimination of Mifepristone is slow, the 
first 50% being eliminated in 12-17hrs followed by a more rapid elimination. 
  T ½ -18hrs. 
 Metabolism via hepatic microsomal enzyme – iso enzyme cytP450-3A4 
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 By 11 days after 600mg of drug 80% is excreted in faeces & 9% in 
urine. 
 Serum levels are undetectable after 11 days. 
CONTRAINDICATIONS FOR MIFEPRISTONE 
1. Confirmed or suspected ectopic pregnancy. 
2. Undiagnosed adnexal mass 
3. IUD in place 
4. Hemorrhagic disorder or concurrent anticoagulant treatment  
5. Inherited porphyrias 
6. Chronic adrenal failure 
7. H/o allergy to Mifepristone or to other prostaglandins  
8. Concurrent steroid treatment.  
-WHO 200230 
DRUG INTERACTIONS 
Drugs that increase the serum level of Mifepristone (through CytP-450-
3A4): 
 Ketoconazole  
 Itraconazole  
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 Erythromycin and  
 Grape Juice 
Drugs that decrease the serum level of Mifepristone  
 Rifampicin 
 Dexamethasone 
 Phenytoin 
 Carbamazepine 
 Phenobarbitone. 
Drug side effects 
 Abdominal pain 
 Uterine cramping  
 Diarrhoea 
 Headache 
 Dyspepsia 
 Pelvic pain 
 Hypertension 
 Hashimoto’s thyroiditis  
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MISOPROSTOL   (C22H38O5) 
 It is a 11-alpha,16-Dihydroxy-16-methy1-9-oxoprost –13E –en-1- oic 
acid methyl ester. It is a synthetic prostaglandin structurally related to PGE1 
 Available as 100 mcg and 200-mcg tablet 
Each tablet has 
♦ Hydrogenated castor oil 
♦ Hydroxy propyl methylcellulose. 
♦ Microcrystalline cellulose 
♦ Sodium starch glycolate 
 Misprostol inhibits gastric acid secretion & promotes bicarbonate 
secretion. It is mucoprotective and is used in drug-induced gastric and in 
duodenal ulcer. Misoprostol softens the cervix, produce uterine contractions 
without exerting any adverse effect on mother and fetus. 
It is also used in second trimester abortion  
No evidence of fetotoxic, teratogenic, carcinogenic effect in animal 
studies.  
- Oriole IM Br.J.Obst.gy. 200043  
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PHARMACOKINETICS 
• Rapidly absorbed orally 
• Rapid de-esterification to its acid which is responsible for clinical 
activity  
• Reaches peak serum level in 15-30 minutes 
• Half-life 20- 40 minutes. 
• Can be stored in ordinary temperature 
• Vaginal application is better than oral route for MTP. 
Dosage 
1. First trimester MTP along with mifepristone 600 mg orally followed 48 
hrs later by 800 mcg of oral or vaginal misoprostol. 
2. Second trimester along with mifepristone in various doses in various 
regimens 
Side effects 
¾ Nausea 
¾ Vomiting 
¾ Headache 
¾ Diarrhea 
¾ Hypotension 
¾ Excessive Bleeding 
¾ Abdominal / Uterine cramps  
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AIMS AND OBJECTIVES 
 
 To assess the efficacy of Mifeprostone & Misoprostol combination 
in first trimester abortion  
 To compare this combination with vaginal Misoprostol alone for 
first trimester MTP 
 To compare the various parameters involved in MTP in both the 
methods & assess the most suitable method for first trimester MTP. 
 
 
 
 
 
 
 
 
 
  29
MATERIALS AND METHODS 
 The present study was carried out at K.A.P.VISWANATHAM 
MEDICAL COLLEGE, TRICHY during academic year 2010-2012. 
The purpose of study is to compare the efficacy of Mifeprostone – 
vaginal Misoprostol combination with vaginal Misoprostol as a method of first 
trimester abortion. 
Study design  : Comparative Study 
Study place   : K.A.P.VISWANATHAM medical college,Trichy.  
Study Population : Patients requesting MTP who attended family  
    welfare/ Planning Dept. at     
    K.A.P.VISWANATHAM medical college,         
    Trichy 
Sample size   : 100 (Random Allocation to either of groups) 
  50 – Mifepristone + Misoprostol Group  
  50 – Misoprostol Group 
Year of Study : July 2010 – July 2011. 
INCLUSION CRITERIA 
1. Confirmed pregnancy upto 9 weeks 
2. Single intra uterine live gestation 
3. No other medical or surgical contra-indication for the procedure. 
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4. Contraceptive failure. 
5.  MTP for social & eugenic causes. 
EXCLUSION CRITERIA 
 Gestation age > 9 weeks 
 Women smoke >10 cigarettes abortion 
 Missed / incomplete / inevitable abortion 
 Suspected ectopic pregnancy  
 Any previous attempts at terminating the present pregnancy 
 Pregnancies with IUD in situ. 
METHODOLOGY 
 All these women were thoroughly investigated before MTP. The work 
up included; 
 Details of patient  
 Investigations 
 Examination of vital signs  
 Abdominal and pelvic examination 
 USG only on Indication 
 Counseling 
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Such of those women who were willing to adhere to the protocol were 
include for the study, provided they fulfilled the inclusion criteria. 
DETAILS OF PATIENT 
Name 
Age, address 
Socio economic status 
Obstetric Formula 
Menstrual history 
Marital history 
Obstetric history  
Medical history 
Surgical history 
Examination of patient 
General Examination 
Abdominal Examination 
Bi-manual pelvic examination 
Routine Investigations like 
   Urine - Albumin 
     Sugar 
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Hb% 
ABO, Rh typing (if not done early) 
VDRL 
HIV [with patient consent] 
All these women are informed about the procedure. 
An informed consent was obtained from these selected women. 
MIFERISTONE – MISOPROSTOL GROUP 
 The Mifeprostone – Misoprostol protocol is an out-patient procedure. 
Very few women who will not be in a position to reach the hospital in time, if 
there is bleeding, severe pain, vomiting etc. were admitted on humanitarian and 
medical grounds. 
Dosage schedule 
Day 1 -  200 mg of Mifepristone was given orally. They were 
 informed about symptoms and were asked to return to  the 
 hospital if the symptoms are severe. 
Day 3 - 400 µg of Misoprostol kept vaginally and observed for  
 4  hrs in OP dept. 90% expelled within 4 hrs. 
 Such of these women who did not expel within 4-6 hrs after vaginal 
Misoprostol were given the option of either going home and coming back on 
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day 15 or admission in the hospital. Such of those women who preferred 
admission were admitted till the abortion is complete. 
 If evacuation is not complete even after 15 days it was considered as 
failure and the patients were offered other methods of termination. 
MISOPROSTOL GROUP 
 50 patients were selected for vaginal Misoprostol method of first 
trimester MTP.   
Procedure 
 Patient was asked to empty the bladder and was asked to lie down in the 
dorsal position with knee semi flexed and hip abducted. After cleaning and 
draping, a Sim’s speculum was introduced into vagina and posterior lip of 
cervix was caught with volsellum. 
 400 µg Misoprostol was kept in posterior fornix and repeated 4 to 6 hrs 
apart depending on response (maximum 3 doses). 
 5 ml of distilled water instilled to dissolve the tablet and facilitate the 
absorption through mucosa. 
 Patient kept in the ward till expulsion is complete – wherever necessary, 
check curettage was performed. 
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 If no expulsion occurred after 20 – 24 hrs it is considered as a failure 
and other interventions offered. 
 Advised about the symptoms like, 
  Nausea / vomiting / diarrhoea 
  Abdominal Cramps 
  Headache  
  Bleeding  
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RESULTS AND ANALYSIS  
TABLE 1: AGE 
S.NO      AGE             Mifepristone + 
             Misoprostol  
        Misoprostol  
No. of 
cases 
% No. of 
cases 
% 
1 18-20 4 8 3 6 
2 21-25 20 40 22 44 
3 26-30 18 36 15 30 
4 >30 8 16 10 20 
 
 Most  of  patients  in  both  the  groups  were  in  age  group  of  20-30 
years(75%). 
 In our study 16% of women from Mifepristone+Misoprostol 
combination belongs to age group of above 30 and only 8% in the above 
combination group were below 20 years. The difference is of minimal 
significance (p = 0.001). 
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DISTRIBUTION OF AGE (18-30 AND ABOVE) 
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TABLE 2: PARITY 
S.No     Parity       Mifepristone + 
       Misoprostol  
        Misoprostol  
No. of 
cases 
% No. of 
cases 
% 
1 UMP 2 4 - 0 
2 Primi 4 8 4 8 
3 G2 36 72 38 76 
4 G3 8 16 8 16 
 
 80% of women is both  groups were parous whereas only 4% unmarried 
pregnancy noted in Mifespristone + Misoprostol group. None of them were 
unmarried in Misoprostol group. 
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DISTRIBUTION OF PARITY 
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TABLE 3 : ANALYSIS OF SOCIO ECONOMIC STATUS 
 
S.NO Status Mifepristone + 
Misoprostol 
Misoprostol 
No. of 
cases 
% No. of 
cases 
% 
1 Class I / II   2 4 0 0 
2 Class III 8 16 6 12 
3 ClassIV/V 40 80 44 88 
       
  ≥ 80%  of  women  in  both  groups  belong  to  Socio-economic  status 
of IV / V. 
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             DISTRIBUTION OF SOCIO ECONOMIC STATUS 
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TABLE 4 : GESTATIONAL AGE 
S.NO Gestational 
Age 
Mifepristone + 
Misoprostol 
Misoprostol 
No. of 
cases 
% No. of 
Cases 
% 
1 <45 Days 30 60 18 36 
2 45-56 Days 15 30 28 56 
3 >56 Days 5 10 4 8 
    
 60% of women in Mifepristone + Misoprostol group where in the 
gestational age of < 45 days whereas only 10% of women where in gestational 
age of above 56 days, on the contrary 56% of women in Misoprostol group 
belong to gestational age of 45-56 days. 
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DISTRIBUTION OF GESTATIONAL AGE 
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TABLE 5: INDUCTION ABORTION INTERVAL 
Characters 
Mifepristone + 
Misoprostol 
(in Hrs). 
Misoprostol 
 
 
Parity  
UMP 5.00 - 
G1 5.00 20 
G2 4.00 18 
G3 3.30 12.40 
 
GA 
<45 3.30-4.00 18 
45-56 4-4.30 18 
>56 days 6.00 24 
 
 When the induction abortion interval between Mifeprostone and 
Misoprotol combination is compared with that of Misoprostol alone it showed 
a ‘p’ value of 0.000 there by indicating that the reduced interval in the 
Mifepristone+ Misoprostol group is significant.  
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INDUCTION – ABORTION INTERVAL 
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INDUCTION – ABORTION INTERVAL 
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TABLE 6: ANALYSIS OF COMPLETE ABORTION 
 
 
 
 
 
SI. 
No 
 
 
 
 
 
Characters 
 
Mifepristone + 
Misoprostol 
 
 
Misoprostol 
 
 
 
 
 
 
P 
value
 
Incomplete
Abortion 
 
 
Method 
Failure 
 
Incomplete
Abortion 
 
Method 
Failure 
 
No. 
Of 
Cases 
 
 
No.
Of 
% 
 
No. 
Of 
Cases
 
No.
Of 
% 
 
No. 
Of 
Cases
 
No.
Of 
% 
 
No. 
Of 
Cases 
 
No. 
Of 
% 
 
1 
 
 
Nullipara 
 
0 
 
0 
 
0 
 
 
0 
 
 
0 
 
0 
 
0 
 
 
0 
 
 
 
0.000 
2 
 
 
Parous 
 
2 
 
4 
 
 
1 
 
2 
 
24 
 
 
48 
 
 
5 
 
 
10 
 
 
 Complete abortion rates in the two groups showed a significant variation 
in favour of Mifepristone – Misoprostol combination. 
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ANALYSIS OF MIFEPRISTONE + 
MISOPROSTOL RESUTS 
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ANALYSIS OF MSOPROSTOL RESULTS 
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TABLE 7 : ANALYSIS OF SYMPTOMS 
 
SI. 
No 
 
Symptoms 
Mifepistone + 
Misoprostol  
Misoprostol  
No. of 
Cases 
% No. of 
Cases 
% 
 
1. 
 
 
Symptom free 
 
0 
 
0 
 
0 
 
0 
 
2. 
 
 
Abd / Ut. cramps 
 
30 
 
60 
 
16 
 
32 
 
3. 
 
 
Excessive 
bleeding 
 
14 
 
28 
 
22 
 
44 
 
4. 
 
 
Vomiting 
 
4 
 
8 
 
12 
 
24 
 
5. 
 
 
Dizziness 
 
2 
 
4 
 
0 
 
0 
 
 Comparing the significance of variables in the symptoms, both groups 
showed statistically incidence of side effects. However a larger study will be 
required to confirm the results ( p = 0.0001). 
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TABLE 8 : ANALYSIS OF POST ABORTIVE 
COMPLICATIONS 
 
 
 
SI. 
No. 
 
 
Conditions 
Mifepristone + 
Misoprostol 
Misoprostol 
 
No. of 
Cases 
 
 
% 
 
No. of 
Cases 
 
% 
 
1. 
 
 
Vomiting 
 
4 
 
8 
 
1 
 
2 
 
2. 
 
 
Persistent 
Bleeding 
 
0 
 
 
0 
 
0 
 
0 
 
 8% of women in Mifepriston + Misoprostol had vomiting whereas 2% 
of women in Misoprotol had vomiting, No women had persistent bleeding in 
both the groups.  
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ANALYSIS OF POST ABORTIVE 
COMPLICATIONS 
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DISCUSSION 
 This study was conducted at K.A.P.VISWANATHAM MEDICAL 
COLLEGE TRICHY during the period of 2010 – 2012. 100 Women were 
included in this study and the outcome analyzed using various parameters. The 
results were subjected to statistical analysis using the T – test -2 tailed one 
sample test and chi-square test. 
Age  (Table – 1) 
 Most of the patients in both the groups were in the age group of 20-30 
years(75%).Women aged 35 years and above were not included in the original 
French study. 
         -WHO-199429 
 In our study 16% of women from Mifepristone – Misoprostol 
combination belongs to the age group of above 30 and only 8% in the above 
combination group were below 20 years. The difference is of minimal 
significance (p=0.001). 
Parity  (Table – 2) 
 Looking at the parity of women seeking MTP in the first trimester it was 
found that more than 80% patient were second gravid, while 4% were 
unmarried. Parity is a major determinant of success rate in medical abortion. 
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 In nulliparous women gestational age has no influence on the outcome 
of pregnancy termination in early weeks. However there was significantly 
lower rates of compete abortion in nulliparous women when age of gestation 
was> 7 weeks. 
    Gestational Age In Days  Complete 
Abortion  
     <49     98.6% 
 Nulliparous    50-56     98.3% 
     57-63     96.4% 
     >63     11% 
 Whereas in parous women the rate of complete abortion was lower after 
7 weeks. 
Gestational Age In Days  Complete 
Abortion  
     <49     96.2% 
 Parous    50-56     93.1% 
     57-63     91.8% 
     >63     10% 
This is a retrospective analysis of 3161 cases by Bartley et al25. 
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 In the present study also 83% of women from both the group were 
parous. 
 Rational for this varied observation in different gestational age still 
remains unexplained. There is no variable significance in parity  
Analysis of Socio-Economic Status (table-3) 
 Most of the women attending our hospital belongs to the marginalized 
group. Hence between 75 and 80% of women in both the groups were from 
socio-economic class of IV and V. Socio-economic status has no influence on 
the outcome. 
Gestational Age (table-4) 
 Gestational age is the most important parameter that determines the 
successful outcome. 
 The influence of duration of pregnancy on successful MTP has been 
extensively studied. Kahn in his meta analysis finds the rate of complete 
abortion to be 96% when period of amenorrhea is <49 days, which declines to 
85% when the gestational age is > 57 days. 
 Though initially medical abortion was used only up to 7 weeks, it has 
been extended to cover even those seeking abortion after 63 days. The rate of 
complete abortion in late MTPs was found to be 94.5% and the same increased 
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to 95.7% when additional dose of 800 µg  of  Misoprostol was introduced 
vaginally. 
- Gouk EV, Lincoln K 44 
 Spitz6 also concur with other studies where it has been established that 
lesser the gestational age more is the success rate. Our study also compare well 
these studies; complete abortion rate being 94% when the period of amenorrhea 
is <49 days. 
Induction-Abortion interval  (table-5) 
 In EL.Refaey et al24, 93% of abortion occurred within 4 hrs of vaginal 
Misoprostol administration in Mifepristone + Misoprostol and 78% occurred 
within 4 hrs if Misoprostol was administered orally. 
 Present study also shows the induction-abortion interval to be only 4 to 
5 hrs following vaginal administration of Misoprostol, which is similar to the 
results of EL. Refaey et al24. 
 The induction abortion interval in this study when vaginal Misoprostol 
alone was used for early MTP was found to be 23 to 24 hrs both in nulliparous 
and parous women. 
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Moreover, the expulsion rate was more in parous women than nulliparous 
women. The study thus has findings similar to the study by Blanchard10, 
Velozco45, and Carbonell et al.18 
 In our study none of the women were Rh negative. Hence there was no 
need for administering anti D immunoglobulin. If the client is Rh negative, 50 
mcg of anti D immunoglobulin should be administered at the time of induction. 
 Thus the combined regimen has more rate of complete abortion with less 
induction-abortion interval than when Misoprostol alone was used.  
Analysis of complete abortion (Table-6) 
 The present study had 2 cases of incomplete abortion in Mifepristone- 
Misoprostol group, the method failure rate was 2%, which indicates that 
additional methods like MVA were used in these patients. These results were 
similar to that of E1 Refaey et al who reported complete abortion rate to be  
95% in vaginal instillation and 87% in oral administration of Misoprostol for 
first trimester MTP. This again shows complete abortion is more with vaginal 
administration than oral route. Peyron et al4 in a 1993 study with Mifepristone–
Misoprostol combination reported 96.9% complete abortion with 0.8% 
incomplete abortion. 
 When Misoprostol was used alone for first trimester MTP, the complete 
abortion rate was found to be only 50% with high rate of incomplete abortion 
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and method failure that made this regime unpopular. Peyron et al4 has shown in 
a study that success rate of Misoprostol when it is used alone is 85% to 95%. 
This concludes that Misoprostol is more effective when it is used in 
combination with Mifepristone than when used alone for medical abortion. 
 All these studies including the present one reaffirms the fact that 
complete abortion rates are more in early pregnancy either with 
Mifepristone+Misoprostol or Misoprostol alone. Similarly, a meta analysis of 
2000 patients reveal that the rate of incomplete abortion is more in parous 
women in Misoprostol group. This difference is statistically significant. 
Analysis of symptoms (Table-7) 
 The symptoms were analyzed and the outcome of the study is 
interpreted as follows: 
 Vomiting was seen in 8% of our patients unlike the study by Cabezas et 
al46 in 1998 where it was 15%. Though Spitz6 reports 100%  bleeding in his 
study, only 28% of our patients had excessive bleeding. Both vomiting and 
bleeding were more when Misoprostol alone was used for MTP (24 and 44% 
respectively). 
 Though blood transfusion was an option if bleeding is prolonged or 
excessive, no such necessity arouse in our study. However blood loss was not a 
common side effect in the WHO, 200030 study also. 
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                60% of women from our study experienced pain that was similar to 
the rate of pain reported by Cabazes et al.46 though pain was noted in many 
patients, it was not very severe. Pain and bleeding increase with increasing 
gestational age in Henshaw  et al.33 
Analysis of post-abortive complications (Table-8) 
 In our study 8% of women from Mifepristone + Misoprostol group had 
vomiting whereas only 2% of women from Misoprostol group had vomiting. 
No patient had persistent bleeding in both the groups. 
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SUMMARY 
 This is a comparative study of medical methods for first trimester 
abortion   conducted at K.A.P.VISWANATHAM MEDICAL COLLEGE, 
TRICHY.          
 Total no. of patients – 100 
 No. of women who were given Mifepristone & Misoprostol  
combination -50 
               No. of  women received Misoprostol alone -50 
Following were the observations of this study. 
1. Most of the patients were in the age group 21-30 and parous 
2. 4% of patients were unmarried who responded well for medical 
methods. 
3. Almost all patients had various symtoms in both groups. 
4. Expulsion was complete in the Mifepristone+Misoprostol group with 
only 2 woman needing check curettage for confirmation of complete 
abortion. However in one women, there was no response and their 
pregnancy was terminated by MVA. On the other hand 48% of women 
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in the Misoprostol alone group had to have curettage for completing the 
abortion process, and 10% of patients there was no response. 
5. Induction-abortion time is less in patients with Mifepristone 
+Misoprostol than Misoprostol alone (4-5 hours vs 20-22 hrs. 
respectively). 
6. None of the patients needed blood transfusion or volume expanders. 
7. None of the patients had delayed bleeding after 45 days. On an average 
Bleeding stopped within 2 to5 days of expelling products. 
8. Misoprostol is less expensive and efficacious. However induction 
abortion interval is prolonged than Mifepristone +Misoprostol 
combination. 
9. Though Mifepristone is more expensive, the high complete abortion rate 
and expulsion withing 4-5 hrs of Misoprostol administration makes it a 
preferred method where cost is not a restraining factor. 
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CONCLUSION 
1. Mifepristone-Misoprostol combination is an effective out-patient 
procedure for early MTP and is ideal for home management. 
2. Complete abortion rate is high with this combination. 
3. Similarly the induction abortion interval with this method is also less. 
4. Other associated complications are less. 
The only confounding factor is the cost involved which is about 20 
times that of Misoprostol alone. 
 This makes the routine use of Mifepristone-Misoprostol combination for 
first trimester abortion an effective option where cost is not a consideration or 
in situations where and early abortion is required. 
 
 
                                      
MASTER CHART  
 
Sl. 
No Age SES Marital 
Status 
OB. 
For GA 
Method Ind-Abo. Interval Results  Sideeffects  
Alternate 
method 
RU486+
  Miso 
Miso RU486+
  Miso 
Miso RU486+
  Miso 
Miso RU486+ 
  Miso 
Miso RU486+
  Miso 
Miso 
1. 19 3 UM UMP <45 1   5.00   1   3       
2. 21 3 M P <45   2   20.00   2   3   D/C 
3. 23 4 M G2  45-56 1   4.00   1   2       
4. 27 4 M G2  >56 1   4.00   1   4       
5. 24 1 M G2  <45   2   18.00   1   1     
6. 22 5 M G2  45-56 1   4.00   1   2       
7. 26 4 M G2  45-56   2   18.20   2   3   D/C 
8. 22 3 M P <45   2   20.20   1   1     
9. 25 4 M G2  45-56 1   4.30   1   4       
10. 28 5 M G2  45-56   2   18.10   2   1   D/C 
11. 31 4 M G3 >56 1   3.30   2   2   D/C   
12. 28 5 M G2  45-56 1   4.00   1   2       
13. 20 3 M G2  <45   2   18.30   2   1   D/C 
14. 35 5 M G3 45-56 1   6.00   2   1   D/C   
15. 21 5 M G2  45-56 1   4.30   1   1       
16. 22 4 M P 45-56 1   5.00   1   1       
17. 27 5 M G2  <45 1   4.00   1   3       
Sl. 
No Age SES Marital Status 
OB. 
For GA Method Ind-Abo. Interval Results  Sideeffects  
Alternate 
method 
RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso 
18. 33 4 M G3 45-56   2   12.35   3   3   MVA
19. 33 4 M G3 45-56   2   12.30   1   1     
20. 18 4 UM UMP >56 1   5.00   1   2       
21. 23 4 M G2  45-56   2   18.00   3   1   MVA
22. 26 3 M G2  45-56 1   4.00   1   1       
23. 26 4 M G2  >56 1   6.00   3   3     MVA
24. 23 1 M G2  45-56 1   4.30   1   1       
25. 30 4 M G3 <45 1   3.30   1   1       
26. 28 4 M G2  <45   2   18.00   2   1   D/C 
27. 26 3 M G2 <45   2   18.00   2   3   D/C 
28. 18 4 M P 45-56 1   5.00   1   1       
29. 27 4 M G2 >56 1   4.30   1   2       
30. 25 5 M G2 >56 1   4.30   1   2       
31. 24 5 M G2 45-56 1   4.30   1   2       
32. 24 3 M G2 <45 1   5.00   1   2       
33. 21 4 M P <45   2   24.00   3   2   MVA
34. 22 4 M G2 <45   2   22.30   2   3   D/C 
35. 32 4 M G2 <45 1   4.00   1   1       
36. 27 5 M G3 45-56 1   4.15   1   1       
Sl. 
No Age SES Marital Status 
OB. 
For GA Method Ind-Abo. Interval Results  Sideeffects  
Alternate 
method 
RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso 
37. 31 5 M G2 45-56 1   4.30   1   1       
38. 29 4 M G2 45-56 1   4.10   1   1       
39. 21 4 M G2 <45 1   3.30   1   1       
40. 22 5 M G2 <45 1   3.30   1   1       
41. 23 5 M G2 <45 1   4.00   1   2       
42. 21 5 M P <45 1   3.30   1   1       
43. 23 4 M G2 45-56   2   18.20   2   2   D/C 
44. 21 4 M G2 <45   2   18.10   3   2   MVA
45. 23 5 M G2 <45 1   3.30   1   1       
46. 31 4 M G2 <45 1   3.30   1   1       
47. 29 5 M G2 <45   2   18.45   1   3     
48. 18 4 M P 45-56 1   5.00   1   1       
49. 32 5 M G3 45-56   2   12.40   2   3   D/C 
50. 26 4 M G2 <45   2   18.00   1   3     
51. 21 5 M G2 45-56 1   4.00   1   2       
52. 21 5 M  G2 45-56 1   4.00   1   1       
53. 21 5 M  G2 45-56 1   4.00   1   1       
54. 33 5 M  G2 <45   2   18.00   2   2   D/C 
55. 27 5 M  G2 <45   2   18.00   2   2   D/C 
Sl. 
No Age SES Marital Status 
OB. 
For GA Method Ind-Abo. Interval Results  Sideeffects  
Alternate 
method 
RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso 
56. 33 4 M  G3 45-56 1   3.30   1   2       
57. 24 4 M  G2 <45   2   18.30   2   2   D/C 
58. 25 5 M  G2 45-56 1   4.00   1   1       
59. 24 5 M  G2 <45 1   3.30   1   1       
60. 23 5 M  G2 <45 1   3.30   1   1       
61. 28 5 M  G2 45-56 1   4.00   1   2       
62. 31 4 M  G2 <45   2   18.00   2   3   D/C 
63. 29 5 M  G2 <45   2   18.00   1   2     
64. 21 5 M  G2 <45   2   18.00   1   2     
65. 29 3 M  G2 45-56 1   4.00   1   1       
66. 23 4 M  G2 45-56   2   18.00   1   2     
67. 31 4 M  G2 <56   2   24.00   2   2   D/C 
68. 30 3 M  G3 45-56   2   18.30   1   2     
69. 19 4 M  P <45   2   18.00   2   2   D/C 
70. 29 4 M  G2 <45   2   18.40   1   1     
71. 24 2 M  G2 <45   2   18.00   1   1     
72. 24 3 M  G2 <45   2   18.00   2   3   D/C 
73. 25 4 M  G2 45-56   2   18.30   2   2   D/C 
74. 23 4 M  G2 45-56   2   18.30   1   2     
75. 34 4 M  G3 45-56 1   3.30   1   2       
Sl. 
No Age SES Marital Status 
OB. 
For GA Method Ind-Abo. Interval Results  Sideeffects  
Alternate 
method 
RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso 
76. 27 3 M  G2 <45   2   18.00   1   3     
77. 22 4 M  G2 <45   2   18.00   1   2     
78. 35 5 M  G2 <45 1   3.30   1   3       
79. 28 4 M  G2 <56   2   24.00   2   2   D/C 
80. 40 4 M  G3 <45   2   12.00   3   1   MVA
81. 27 4 M  G2 45-56 1   4.30   1   1       
82. 19 5 M  G2 45-56   2   18.00   1   3     
83. 26 3 M  G3 <45   2   12.40   2   2   D/C 
84. 22 4 M  G2 45-56 1   4.30   1   1       
85. 30 4 M  G2 45-56 1   4.00   1   1       
86. 22 4 M  G3 <45   2   12.00   2   2   D/C 
87. 31 4 M  G2 >56 1   6.00   1   1       
88. 23 4 M  G2 45-56   2   18.40   2   1   D/C 
89. 29 5 M  G3 <45   2   12.00   1   2     
90. 25 5 M  G2 45-56   2   18.30   1   1     
91. 29 5 M  G2 <45 1   4.00   1   1       
92. 24 4 M  G2 <45   2   18.00   2   1   D/C 
93. 29 5 M  G2 >56   2   24.00   1   1     
94. 28 4 M  G2 45-56   2   18.30   2   2   D/C 
95. 23 4 M  G3 <45 1   3.30   1   1       
Sl. 
No Age SES Marital Status 
OB. 
For GA Method Ind-Abo. Interval Results  Sideeffects  
Alternate 
method 
RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso RU486+ Miso 
96. 21 5 M  G2 45-56   2   18.00   1   1     
97. 26 3 M  G2 <45   2   18.10   2   2   D/C 
98. 36 4 M  G3 45-56 1   3.30   1   1       
99. 31 5 M  G2 <45   2   18.00   1   1     
100. 22 5 M  G2 <45   2   18.00   1   2     
 
 BIBLIOGRAPHY 
1. Crenin MD, Edwards.J. Early abortion-surgical and medical 
options,current problem obst gynaecology fertile 1997 ; 20;6-32.  
2. Kahn JG, Becker BJ, Maclsaa L, Amory JK, Neuhas J, O1kin I, Creinin 
MD. The efficacy of medical abortion: a meta – analysis. Contraception; 
61 (1) : 29-40, January 2000. 
3. Ashok PW, Penney GC, Flett GM, Templeton A. An effective regimen 
for early medical abortion: a report of 2000 consecutive cases. Human 
Reporduction ; 13:2962-5, 1998. 
4. Peyron R, Aubeny E, Targosz V, Silvestre L, Renault M, Elkik P et al. 
Early termination of pregnancy with Mifepristone (RU 486) and the 
orally active prostaglandin Misoprostol. N Engl J Med; 328: 1509 -13, 
1993. 
5. Schaff  EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Boppems S. 
Low dose Mifepristone 200 mg and vaginal misoprostol for abortion.                  
Contraception ; 59 :1 -6, 1999. 
6. Spitz IM, Bardin CW, Benton L, Robbins A. Early Pregnancy 
termination with Mifepristone and Misoprostol in the United States. N 
Engl J Med; 338:1241-5,1998.  
 7. Trussell J and Ellertson C. (1998) Estimating the efficacy of medical 
abortion. Conception 60:119 -135. 
8. Urqutart DR, Templeton AA, Shinewi F, Chapman M, Hawkins K, 
Mcgarry J, Rodger M, Barid DT et al. (1997) The efficacy and tolerance 
of  Mifepristone and prostaglandin  in termination of pregnancy of less 
than 63 days gestion; UK multicentre study – final results. 
Contraception 5: 1-5. 
9. Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Ziao B, Gu S, Du MK, 
Krishna UR Eschen A and Ellertson C. (1997) Safety, efficacy, and 
acceptability of medical abortion in china, Cuba and India: a 
comparative trial of Mifepristone – Misoprostol versus surgical abortion. 
American Journal of Obsterics and Gynecology 176 : 431-437. 
10. Blanchard K, Winikoff  B, Coyaji K, Nguyan TN. Misoprostol alone– 
new method of medical abortion ? J american Med Women’s Assoc; 55 
(3 Suppl): 189-90, 2000. 
11. Ngai SW, Tang OS, Chen YM, Ho PC. Vaginal Misoprostol alone for 
medical abortion up to 9 weeks of gestation: efficacy accountability. 
Ann Reprod; 15: 1159-62, May 2000. 
12. Tang OS, Ho PC, pilots study on the use of sublingual Misoprostol for 
medical abortion. Contraception 2001;64:315-7A. 
 13. Kuldip Singh et al prostaglandins in MTP BJOG, Feb 2003; 110: 175-
180. 
14. RCOG – Royal College of Obstetricians and Gynaecologists. (2004). 
The care of women requesition induced abortion. Evidence – based 
guideline No. 7. London, RCOG Press.  
15. Crenin MD, Pymar  HC, Medical abortion alternative to mifepristone 
J.Am Med women association 53 (3 suppl): 127-32,2000. 
16. Ozeren M, Bilekli C, Aydemir V, Bozkaya H. Methotrexate and 
Misoprostol used alone or in combination for early abortion. 
Contraception; 59(6)-: 389-94, June 1999. 
17.  Wiebe ER. Comparing abortion induced with Methotrexate and 
Misoprostol to Methotrexate alone. Contraception; 59 (1) : 7-10, January 
1999. 
18. Carbonell Esteve JL, Varela L, Velazco A, Tanda R, Sanchez C. 25 mg 
or 50 mg of oral Methotrexate followed by vaginal Misoprostol 7 days 
after for early abortion: a randomized trial. Gynecol Obstet Invest;  
47 (3): 182-7,1999. 
19. Hausknecht RU. Methotrexate and Misoprostol to terminate early 
pregnancy. N Engl J Med; 333 (9) : 537-40, August 31, 1995. 
 20. Mckinley C, Thong KJ and Baird DT. (1993) The effect of dose of 
Mifepristone on gestation and the efficacy of medical abortion with 
Mifepristone and Misoprostol. Human Reproduction 8:1502-1505. 
21. Word Health Organization Task Force on Post- ovulatory Methods for 
Fertility Regulation. (1993) Termination of pregnancy with reduced 
doses of Mifepristone. British Medical Journal 307: 532-537. 
22. Schaff EA, Eisinger SH, Stadalms LS, Franks P, Gore BZ and Popperna 
S.(1999) low –dose Mifepristone 200 mg and vaginal misoprostol for 
abortion. Contraception 59:1-6. 
23. World Health Organization Task Force on Post – ovulatory Methods for 
fertility regulation. Lowering the dose of Mifepristone and Gemeprost 
for early abortion : a randomized cotrolled trial. BJOG; 108 (7) 738-42, 
July 2001. 
24. E1-Refaey    H,   Rajasekar   D,    Abdalla   M,   Calder   L  and  
Templeton A. (1995) Induction  of  abortion  with  Mifepristone   
(RU486) and  oral or vaginal misoprostol. New England Journal of 
Medicine 382: 983-987. 
25. Bartely  J.  Tong  S, Everington D. Baird DT. Contraception 2000; 62:             
297-303. 
 26. Helene,Mifepristone and Misoprostol  use in early abortion BJOG, Sep 
2003;  110:808-818. 
27. ICMR, Task Force on Anti-implanatation / Menstrual regulating agents, 
Study Protocol, New Delhi, 1994. 
28. Aubeny B. Baulieu EE. Academic des Sciences Paris 1991:312:539. 
29. WHO Abortion, 2nd edn, World Health Organization,Geneva, 1994. 
30. World  Health  Organization  (2000b)  Improving  access  to  quality   
care     in family planning : medical eligibility criteria for contraceptive 
methods. Second edition. Geneva, World Health Organization, (WHO/ 
00.02). 
31. Baulieu EE. Contragestation and other clinical application of 
Mifepristone and antiprogestin at the receptor gene. 1989, (145 : 1351 -
1357)  Medline. 
32. Rodger MW, Baird DT, Pretreatment with Mifepristone reduces interval 
between prostaglandin and expulsion-second trimester abortion. BJOG 
ob gynec. 1990;97,41-45 (medline). 
33. Henshaw RC, Templeton AA, Antiprogesterone. Progress in obstetrics 
and gyn vol.10 Ed.John Studd pp 259-279, Churchill Livingston 1993. 
 34. Baird DT. In : Drife JO, Baird DT (des) Contraceptive Research for 
today,   Livingston, 1993 : 73. 
35. Wolf JP, Ulmann A, Baulieu EE, Contraception Potency of Mifepristone 
by Ovulation inhibiton and Suppression of Pituitary gonodotrophin 
secretion in vitro Contraception 1989; 40:185 -193 (medline). 
36. Van Sankon MR, Haspel AA, Contraception 1989a; 35:423. 
37. IPPF. Inter plan parent med Bull 1994; 28(6): 1. 
38. Urquahat  DT. Templeton AA. Mifepristone for cervical priming for 
surgical method of abortion in first trimester contraception 1990;  
42: (191-199). Medline. 
39. Kettel LM, Murphy AA, Ulmann AS. Yen SS, endocrinal response to 
long term administration of the antiprogestine. Mifepristone regular 
endo trimester fertility contraception 1991, 56 : 402 -407 (medline). 
40. Howitz KB, Murphy AA, Kettel LM, Regression of uterine leiomyoma 
a response to antiprogestin on clinical endocrine metabolism 1993; 
76:513-517 (Abstract). 
41. Grunberg  SM. Weizz MA, treatment of unresectable meningioma with 
antiprogestin Mifepristone, Neuro surgery 1991 : 74 : 861-866 
(medline). 
 42. Nieman LK,. Successful treatment of cushings syndrome with 
glucocorticoids, Mifepristone, J. clinical endocrine metabolism 1985; 
61:536-50 (abstract). 
43. Oriole IM, Catilla EE, Epidemiological assessment of misoprostol 
teratogenicity, BJOG; 107(4) : 519-23, April 2000. 
44. Gouk EV, Lincoln K, Khair A, Haslock J, Knight J, Cruickshank DJ. 
Medical termination of pregnancy at 63 to 83 days gestation. Br J obstet 
Gynaecol; 106 :535-39, 1999.  
45. Velozco A, Varela L, Tanda R, Sanchez C, Barambio S, Chani S, Valero 
F, Aragon S, Mari J, Carbonell JL. Misoprostol  for abortion up to  
9 weeks in adolescents. Eur J contraception and reproductive health 
care; 5(4) : 227-33, December 2000. 
46. Cabezas E. Medical versus surgical abortion. International Journal of  
Gynaecology and Obstetrics; 63 supplement LS141-6, December 1998. 
